In a small study, researchers assessed the mechanistic basis of unusual vertical jerky eye oscillations seen in patients clinically diagnosed with progressive supranuclear palsy.

Researcher sought to assess the incidence and mortality from ALS in NFL athletes and to describe the characteristics associated with ALS incidence in this cohort.

Researchers sought to compare various high-caloric food supplements as add-on therapy to normal food intake and standard treatment in patients with ALS.

Elivaldogene autotemcel (eli-cel) is a one-time gene therapy designed to add functional copies of the ABCD1 gene into a patient’s own hematopoietic stem cells, resulting in the production of ALDP.

Researchers sought to investigate the association between lower retinal nerve fiber layer thickness, a marker of neurodegeneration, with clinically relevant depressive symptoms and depressive symptoms over time.

The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD.

Researchers sought to develop a “roadmap” to early intervention and disease prevention for ALS by observing advances in neurodegenerative diseases with a presymptomatic period.

The researchers sought to determine whether motor signs in Huntington disease (HD) would be associated with altered indirect pathway connectivity, and whether apathy in early HD is linked to change in direct pathway connectivity.

Trofinetide is a novel synthetic analogue of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome.

In a PET imaging study, researchers assessed synaptic damage and its clinical correlates in early Huntington disease in vivo.

Using data from 2 of the largest cohort imaging studies in Huntington disease (HD), researchers utilized a disease progression model to learn individual-level disease times and reveal a new timeline of structural MRI changes in HD.

Investigators used data from the Enroll-HD registry to assess patterns of treatment for chorea in patients with Huntington disease.

Researchers analyzed cerebrospinal fluid and serum from patients with ALS to determine diagnostic biomarkers for the development of early treatment strategies.

Population-based health record linkage data were used to examine risk of neurodegenerative diseases among former soccer players vs a matched general population control group.

Investigators evaluated whether dextromethorphan/quinidine could offer long-term improvement in bulbar impairment in individuals with ALS, thus prolonging the use of noninvasive respiratory muscle aids and increasing survival.

A team of researchers assessed COVID-19 outcomes in patients with neurodegenerative diseases compared with patients without such disease.

Study researchers evaluated the role of biomarkers in predicting conversion to clinically manifest α-synucleinopathies in patients with isolated REM sleep behavior disorder.

Arimoclomol is an investigational oral drug candidate that is designed to amplify and sustain the cellular production of heat shock proteins.

Researchers from South America presented a protocol for a randomized trial to study the effects of an optimized home-based respiratory care approach in patients with ALS.

LYS-GM101 is a gene therapy designed to replace the gene mutation and restore the production of the beta-galactosidase enzyme.

Investigators aimed to assess lifestyle during the presymptomatic phase of ALS, stratified by C9orf72 mutation, and examine evidence about whether lifestyle factors are causative factors.

Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.

Participants in the multidisciplinary intervention group had significant improvements in verbal learning and memory, attention, cognitive flexibility, and processing speed.

The researchers found that 73.5 percent of the 737,839 community-dwelling beneficiaries with dementia were prescribed any CNS-active medication.

The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Evrysdi is a survival motor neuron-2 (SMN2) splicing modifier.

Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.

Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.

Investigators assessed patients with sporadic ALS to determine the relationship between somatosensory cortex excitability and survival prognosis.